recurrent breast cancer
Health authorities in the Kingdom are attracting a new treatment to combat advanced breast cancer, after it was approved by the Food and Drug Administration in the United States of America.
This treatment comes as an exceptional milestone in the field of breast cancer, reinforcing doctors'' strategies in overcoming most symptoms of recurrent cancer.
And Dr. explained. Nadia Harbeck, Professor and Head of the Breast Oncology Center at the University of Munich, Germany and Head of the Oncology and Clinical Trials Unit at the University of Gynecology in Munich, said that this new development represents a positive change in the field of breast cancer treatment, as the cadsaila serum (T-DM1) has strong therapeutic capabilities on Patients with advanced breast cancer (HER2), noting that it works to transfer the offensive substances to cancer cells without healthy cells, so it is considered a revolutionary method in treating breast cancer without causing hair loss and nausea for patients.
For her part, Dr. said. Atlal Abu Sanad is a consultant oncologist and clinical researcher in the field of molecular tumors at King Abdulaziz University in Jeddah, that this development is a promising treatment and it is a biologically modified antibody carrying a chemical substance that enhances the doctors'' ability to overcome most symptoms of the disease in addition to its contribution to increasing the life expectancy of patients with freedom The patient is one of the cells of the disease, adding, "Now we are able to deal with cancer as a potentially cure disease or make it a chronic disease with medication for long periods, but there are many patients who still lose their lives due to the spreading cancer, so we must continue to participate in scientific and clinical research and encourage it."
Dr. Hamdan Al-Suwailin, consultant hematologist at Saad Specialist Hospital in Dammam and head of the Hematology and Oncology Division, indicated that breast cancer is the most common tumor among women in the Kingdom and represents 13% of the total tumors in the Kingdom, and nearly 40% of cases are diagnosed in advanced stages of the disease. Every five women have the aggressive type protein that is receptor positive (HER2) at a rate of 20-25%, which is a fierce and lethal form of cancer that was difficult to treat and carries high rates of relapse rates upon late detection, especially when the tumor is large in size and its effect reaches the neighboring lymph nodes. .
